Sign in

NRSN on Nasdaq

NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd. is a pharmaceutical preparations company, listed on Nasdaq (NRSN).1

Price unavailable

Last updated Oct 21, 2026.

Overview

-$11.1MNet income, fiscal 20252

Compare with another stock.

  • TickerNRSN on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersL31
  • Incorporated inIsrael3
  • Business address11 Hamenofim St., Building B, Herzliya, L3 46725623
  • Filer categoryNon-accelerated filer, Emerging growth company3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Ordinary Shares and Warrants are traded on The Nasdaq Capital Market under the symbols “NRSN” and “NRSNW,” respectively.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-$7.7MFree cash flow2

Financial statements

Operating income67582-$11.1M in 2025+798% since 2019
-$15.0M-$10.0M-$5.0M02019: -$1.2M-$1.2M20192020: -$2.9M-$2.9M2020+134%2021: -$5.6M-$5.6M2021+93%2022: -$10.6M-$10.6M2022+89%2023: -$12.0M-$12.0M2023+14%2024: -$9.9M-$9.9M2024−18%2025: -$11.1M-$11.1M2025+12%
Net income67582-$11.1M in 2025+810% since 2019
-$15.0M-$10.0M-$5.0M02019: -$1.2M-$1.2M20192020: -$2.8M-$2.8M2020+131%2021: -$4.0M-$4.0M2021+43%2022: -$10.5M-$10.5M2022+160%2023: -$10.1M-$10.1M2023−4%2024: -$10.2M-$10.2M2024+1%2025: -$11.1M-$11.1M2025+9%

Every line of the income statement as filed: the last 3 fiscal years, latest first.2

Period ending2025-12-312024-12-312023-12-31
Research and development expenses-$6.2M-$5.7M-$7.3M
General and administrative expenses-$4.9M-$4.2M-$4.8M
Operating loss-$11.1M-$9.9M-$12.0M
Financing income (expenses), net-$40.0K-$308.0K$1.9M
Net loss and comprehensive loss-$11.1M-$10.2M-$10.1M
Basic net loss per share (in Dollars per share)-$0.44-$0.54-$0.74
Diluted net loss per share (in Dollars per share)-$0.44-$0.54-$0.74
Weighted average number of ordinary shares used in computing basic net loss per share (in Shares)25.5M shares18.6M shares13.6M shares
Weighted average number of ordinary shares used in computing diluted net loss per share (in Shares)25.5M shares18.6M shares13.6M shares

Compare NeuroSense Therapeutics Ltd. with another company

Corporate structure

NeuroSense Therapeutics Ltd. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of NeuroSense Therapeutics Ltd.

  • Rimon Gold Assets Ltd Filed SC 13G on NeuroSense Therapeutics Ltd., latest Dec 9, 2024
  • Alon Ben-Noon Filed SC 13G/A on NeuroSense Therapeutics Ltd., latest Feb 13, 2024 (3 filings since Dec 23, 2021)
  • Ariel Gordon Filed SC 13G/A on NeuroSense Therapeutics Ltd., latest Feb 13, 2024 (3 filings since Dec 20, 2021)
  • E Europe Ltd Filed SC 13G/A on NeuroSense Therapeutics Ltd., latest Mar 15, 2023 (2 filings since Dec 30, 2021)
  • Real Property International Ltd Filed SC 13G on NeuroSense Therapeutics Ltd., latest Mar 15, 2023
  • NeuroSense Therapeutics Ltd. L3

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What NeuroSense Therapeutics Ltd. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$134.0K2 Dec 31, 2025$126.0K2 Dec 31, 2024+6.3%
Accumulated depreciation$76.0K2 Dec 31, 2025$60.0K2 Dec 31, 2024+26.7%
Property and equipment, net$58.0K2 Dec 31, 2025$66.0K2 Dec 31, 2024−12.1%
Operating-lease assets (leased space)$170.0K2 Dec 31, 2025$84.0K2 Dec 31, 2024+102.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$166.0K2 Dec 31, 2025$3.4M2 Dec 31, 2024−95.1%

Leadership

Who has led NeuroSense Therapeutics Ltd., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Alon Ben-Noon2026–now

Chief financial officer

  1. Or Eisenberg2026–now
Board members and other officers (8)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorChristine Pelizzari named Jul 5, 2023 to Dec 12, 202419
  • DirectorCaren Deardorf named Jul 5, 2023 to Apr 25, 202420

Timeline

  1. Mar 30, 2026New chief executive Alon Ben-Noon becomes CEO9

Filings

306 filings to the SEC since October 2021: 5 annual reports, 15 insider forms, 10 large holders, 3 private raises, 273 other. The latest 20:

  1. Oct 13, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  2. Oct 2, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  3. Sep 25, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  4. Sep 9, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  5. Aug 27, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  6. Aug 13, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  7. Aug 6, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  8. Jul 31, 2026EFFECT EDGAR
  9. Jul 31, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  10. Jul 31, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  11. Jul 30, 2026F-3/A AMENDMENT NO. 1 TO FORM F-3 EDGAR
  12. Jul 22, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  13. Jun 29, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  14. Jun 25, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  15. Jun 17, 20264 EDGAR
  16. Jun 17, 20264 EDGAR
  17. Jun 11, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  18. Jun 9, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  19. Jun 8, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  20. Apr 28, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR

The 306 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 2 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 16, 2026Ben-Noon AlonChief Executive OfficerBuy250,000$0.80$200.0KForm 4
Jun 16, 2026Eisenberg OrChief Financial OfficerBuy250,000$0.80$200.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Dec 5, 2024Raised $5 million in a private offering of securities Form D: 2 investors so far Form D
  2. Apr 15, 2024Raised $4.5 million in a private offering of securities Form D: 1 investor so far Form D
  3. Jul 5, 2023Raised $4.5 million in a private offering of securities Form D: 1 investor so far Form D

SEC filer profile

How NeuroSense Therapeutics Ltd. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARNeuroSense Therapeutics Ltd.1
  • CIK0001875091
  • Filer statusNon-accelerated filer an emerging growth company; not a shell company4
  • Incorporated inIsrael4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address11 Hamenofim St., Building B, Herzliya, L3 46725621
  • Phone972-9-95311421
  • Shares outstanding32,557,174 shares as of Dec 31, 20254
  • AuditorSomekh Chaikin, Tel Aviv, Israel PCAOB ID 1057; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceAug 9, 20211
  • Filings311 in all: 6-K (170), EFFECT (17), 424B3 (16), CORRESP (15), 3 (10), POS AM (10), UPLOAD (10), 424B5 (7)1
    All 28 form types

    F-1/A (7), 20-F (5), 4 (5), F-3 (5), SC 13G (5), SC 13G/A (5), F-1 (4), D (3), DRSLTR (3), DRS/A (2), FWP (2), S-8 (2), 424B4 (1), 6-K/A (1), 8-A12B (1), AW (1), CERT (1), DRS (1), F-3/A (1), POS EX (1)

  • Latest filingsAnnual report (20-F) Mar 31, 2026

Securities registered for trading

ClassSymbolExchange
Ordinary Shares, no par value per shareNRSNNasdaq
Warrants, exercisable for one ordinary shareNRSNWNasdaq

From the cover page of the 20-F filed Mar 31, 2026 (Section 12(b) of the Exchange Act).4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25